To the best of our knowledge, this is the first study ever conducted to investigate the relationship between endogenous GLP-1 levels and glycaemic control as well as insulin responses to DPP-IV inhibition in the form of linagliptin therapy in both prediabetes and T2D subjects. This evidence concerns the gene INS and prediabetes syndrome.